Cipher Pharmaceuticals (TSE:CPH) Price Target Lowered to C$17.00 at Stifel Nicolaus

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price target reduced by equities research analysts at Stifel Nicolaus from C$19.00 to C$17.00 in a research report issued to clients and investors on Monday,BayStreet.CA reports. Stifel Nicolaus’ price target points to a potential upside of 30.77% from the stock’s previous close.

CPH has been the topic of several other research reports. Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th. Stifel Canada raised shares of Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Cipher Pharmaceuticals Stock Down 6.3 %

CPH stock traded down C$0.88 on Monday, reaching C$13.00. 89,016 shares of the company traded hands, compared to its average volume of 47,217. The firm has a fifty day simple moving average of C$16.19 and a 200-day simple moving average of C$12.27. Cipher Pharmaceuticals has a one year low of C$5.03 and a one year high of C$19.69. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67. The company has a market cap of C$332.67 million, a P/E ratio of 10.41 and a beta of 1.20.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing the consensus estimate of C$0.03 by C($0.02). The business had revenue of C$14.15 million during the quarter, compared to the consensus estimate of C$13.37 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Research analysts anticipate that Cipher Pharmaceuticals will post 1.2907348 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.